KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Inventory (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Inventory for 16 consecutive years, with $185.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Inventory changed N/A to $185.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $185.8 million, a N/A change, with the full-year FY2024 number at $141.9 million, up 11.17% from a year prior.
  • Inventory was $185.8 million for Q3 2025 at Halozyme Therapeutics, up from $141.9 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $185.8 million in Q3 2025 to a low of $47.8 million in Q1 2022.
  • A 5-year average of $96.9 million and a median of $100.1 million in 2022 define the central range for Inventory.
  • Peak YoY movement for Inventory: fell 18.14% in 2022, then skyrocketed 125.12% in 2023.
  • Halozyme Therapeutics' Inventory stood at $53.9 million in 2021, then skyrocketed by 85.73% to $100.1 million in 2022, then increased by 27.44% to $127.6 million in 2023, then grew by 11.17% to $141.9 million in 2024, then skyrocketed by 30.97% to $185.8 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Inventory are $185.8 million (Q3 2025), $141.9 million (Q4 2024), and $127.6 million (Q4 2023).